Regeneron and Sanofi-Aventis collaborate to develop antibodies
As part of the research agreement, Sanofi-Aventis will make an $85 million upfront payment to Regeneron and will fund up to $475 million of research over the next
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.